Technology Licensing opportunities

Available technologies

Clear search
Charcot-Marie Tooth Disease model

Model for Charcot-Marie Tooth Disease

Novel inhibitor of neuropathic pain

This novel neutralising antibody-based approach offers an innovative and valuable therapeutic strategy for patients with neuropathic pain.

Novel protein fragment of von Willebrand’s factor for treating VWD and haemophilia A

Novel truncated fragments of von Willebrand factor (VWF) engineered by a team at Imperial College London.

PEGylated nanomaterials

PEG functionalised graphene is a novel nucleant specifically designed for automated and high throughput crystallisation experiments.

Lactobacillus ST peptide for therapeutic use against inflammatory bowel disease

66aa, ~7kDa serine/threonine-rich protein (STp) derived from Lactobacillus plantarum, resistant to proteolysis and with an immunomodulatory effect representing a potential novel therapeutic for IBD.

Subscribe for Licensing Opportunities updates
Keep up to date with new technologies and licensing opportunities coming out of Imperial College London